Matthew Kurian: Does the Clock Matter in Cancer Care?
Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine, shared a post on LinkedIn:
“Does the Clock Matter in Cancer Care?
At ASCO 2025, one of the most intriguing and pragmatic findings wasn’t about what we give – but when.
In advanced non-small cell lung cancer, two studies presented this year raised eyebrows:
1. Large Bi-continental Retrospective Study (713 patients):
• Found that giving immunotherapy + chemo before ~11:30 AM was tied to significantly better outcomes:
• Improved overall survival, progression-free survival, and response rates
2. Phase III Randomized Trial (Zhang et al.):
• Confirmed the finding prospectively—early infusions (before 3 PM) led to:
• PFS: 11.3 vs 5.7 months
• OS Hazard Ratio: 0.45 (~55% reduction in risk of death)
Why does this matter?
• It’s a low-cost, pragmatic strategy to potentially improve outcomes—no new drugs required.
• But it raises real-world questions:
• Does this apply to other tumor types?
• How do we operationalize this when infusion chairs are already packed?
Sometimes improving outcomes isn’t about adding more – it’s about doing the same things smarter.
Is your center thinking about timing of IO yet? How would you handle this logistically? And lastly, are you convinced?”
More posts featuring Matthew Kurian on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023